Cellectis
CLLS
#7480
Rank
โ‚น38.23 B
Marketcap
โ‚น380.10
Share price
5.03%
Change (1 day)
214.02%
Change (1 year)

P/E ratio for Cellectis (CLLS)

P/E ratio as of February 2026 (TTM): -6.15

According to Cellectis's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -6.14706. At the end of 2022 the company had a P/E ratio of -0.8974.

P/E ratio history for Cellectis from 2015 to 2025

PE ratio at the end of each year

Year P/E ratio Change
2022-0.8974-67.62%
2021-2.77-80.03%
2020-13.995.35%
2019-7.10-16.8%
2018-8.54-17.98%
2017-10.417.95%
2016-8.83-81.69%
2015-48.2

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Regeneron Pharmaceuticals
REGN
18.2-395.89%๐Ÿ‡บ๐Ÿ‡ธ USA
uniQure
QURE
-6.78 10.24%๐Ÿ‡ณ๐Ÿ‡ฑ Netherlands
Novavax
NVAX
4.50-173.13%๐Ÿ‡บ๐Ÿ‡ธ USA
Flexion Therapeutics
FLXN
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.